Skip to main content
SpringerLink
Log in

Tuberculosis Infection in a 58-Year-Old with Psoriasis

  • Chapter
  • First Online:
Clinical Cases in Psoriasis

Part of the book series: Clinical Cases in Dermatology ((CLIDADE))

  • 743 Accesses

Abstract

A 58-year-old male with a 10-year history of psoriasis presented to the clinic for worsening of psoriasis after a month-long hospital admission for a military tuberculosis infection. The patient received antituberculous medications during his admission and was advised to continue the regimen for an additional 8 months. At that time, his psoriasis medication, adalimumab, was immediately discontinued. Subsequently, his psoriasis worsened, affecting a significant proportion of his body. The patient was previously using adalimumab for 3 years with considerable benefit. Of note, before starting adalimumab, the patient tested positive for latent tuberculosis and was prescribed isoniazid. However, it was unclear if the patient was compliant with his medication. The patient denied fever, chills, and night sweats. However, he continued to experience fatigue and poor weight gain. He did not have any other medical conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–24. doi:10.1136/annrheumdis-2011-201244. Review.

    Article  CAS  PubMed  Google Scholar 

  • CDC. Reported Tuberculosis in the United States 2014. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2015.

    Google Scholar 

  • Chimenti MS, Gramiccia T, Saraceno R, Bianchi L, Garofalo V, Buonomo O, Perricone R, Chimenti S, Chiricozzi A. Apremilast for the treatment of psoriasis. Expert Opin Pharmacother. 2015;16(13):2083–94. Review.

    Article  PubMed  Google Scholar 

  • Cohn DL, O’Brien RJ, Geiter LJ, Gordin FM, Hershfield E, Horsburgh CR. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2000;49(6):1–54.

    Google Scholar 

  • Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209–17.

    Article  PubMed  Google Scholar 

  • Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41(Suppl 3):S199–203.

    Article  CAS  PubMed  Google Scholar 

  • Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35. doi:10.1056/NEJMra1405427. Review.

    Article  CAS  PubMed  Google Scholar 

  • Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176–82.

    Article  CAS  PubMed  Google Scholar 

  • Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 Investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.

    Article  CAS  PubMed  Google Scholar 

  • Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford). 2005;44(6):714–20. Review. PubMed PMID: 15741198.

    Article  CAS  PubMed  Google Scholar 

  • Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.

    Article  CAS  PubMed  Google Scholar 

  • van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.e4.

    PubMed  Google Scholar 

  • Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology. 2010;15(4):603–22. doi:10.1111/j.1440-1843.2010.01751.x. Review.

    Article  PubMed  Google Scholar 

  • Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1–25.

    PubMed  Google Scholar 

  • Menter A, Thaçi D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, Rubant S, Williams DA. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73(3):410–9.e6. doi:10.1016/j.jaad.2015.06.038. PubMed PMID: 26190240.

    Article  PubMed  Google Scholar 

  • Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO, Japanese Ixekizumab Study Group. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2016. doi:10.1111/1346-8138.13622. [Epub ahead of print] PubMed PMID: 27726163.

  • Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen YK, Leonardi C, PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145–52.

    Article  CAS  PubMed  Google Scholar 

  • Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol. 2002–2003;34(4):551–3.

    Article  CAS  PubMed  Google Scholar 

  • Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Loma Linda University School of Medicine, Loma Linda, CA, USA

    Daniel J. No

  2. Saint Louis University School of Medicine, St. Louis, MO, USA

    Kavita Darji

  3. University of California, Riverside School of Medicine, Riverside, CA, USA

    Mina Amin

  4. Wu Medical Associates, Inc., Los Angeles, CA, USA

    Jashin J. Wu

Authors
  1. Daniel J. No
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kavita Darji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mina Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jashin J. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jashin J. Wu .

Editor information

Editors and Affiliations

  1. Wu Medical Associates, Inc., Los Angeles, California, USA

    Jashin J. Wu

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

No, D.J., Darji, K., Amin, M., Wu, J.J. (2017). Tuberculosis Infection in a 58-Year-Old with Psoriasis. In: Wu, J. (eds) Clinical Cases in Psoriasis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-52779-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52779-6_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52778-9

  • Online ISBN: 978-3-319-52779-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation